<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366361">
  <stage>Registered</stage>
  <submitdate>18/05/2014</submitdate>
  <approvaldate>27/08/2015</approvaldate>
  <actrnumber>ACTRN12615000895583</actrnumber>
  <trial_identification>
    <studytitle>The effect of implantation of biventricular pacemaker with or without defibrillator on blood vessels function and electrical changes in the hearts  of patients with severe heart failure


</studytitle>
    <scientifictitle>The effect of implantation of biventricular pacemaker with or without defibrillator on endothelial functions and electrical and mechanical cardiac  remodelling in patients with severe heart failure after 6months.</scientifictitle>
    <utrn>None</utrn>
    <trialacronym>InCARP</trialacronym>
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Implantation of biventricular pacemaker with or without automatic implantable defibrillator according to conventional indications. The approximate duration of the implantation procedure is 2 to 3 hours</interventions>
    <comparator>Uncontrolled</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
    <interventioncode>Treatment: Surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary end point of the study will be change in augmentation index response to salbutamol post cardiac resynchronisation therapy. 
Salbutamol is administered as part of the primary outcome assessment. Augmentation index is assessed by pulse wave analysis using radial artery application tonometry

This outcome will be compared between responders and non- responders of cardiac resynchronisation therapy</outcome>
      <timepoint>6months post implantation of the biventricular pacemaker with or without a defibrillator</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The magnitude of the primary endpoint  will be correlated with the extent of improvement of 6 minute walk distance

This outcome will be compared between responders and non- responders of cardiac resynchronisation therapy</outcome>
      <timepoint>6months post implantation of the biventricular pacemaker with or without a defibrillator</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Change in redox stress in responders and non responders. This is done by measuring change in thioredoxin interacting protein levels in platelets, measuring levels of asymmetric dimethyl arginine levels in plasma</outcome>
      <timepoint>6months post implantation of the biventricular pacemaker with or without a defibrillator </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>VO2 max using bicycle ergometer

This outcome will be compared between responders and non- responders of cardiac resynchronisation therapy</outcome>
      <timepoint>6months post implantation of the biventricular pacemaker with or without a defibrillator</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>left ventricular ejection fraction as well as degree of dyssynchrony using2D and 3D echocardiogram

This outcome will be compared between responders and non- responders of cardiac resynchronisation therapy</outcome>
      <timepoint>6months post implantation of the biventricular pacemaker with or without a defibrillator</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change in electrical parameters such as QRS duration, PR intervals, right ventricular refractory periods, biventricular conduction intervals.
These are measured using the implanted device. These are composite secondary outcome.

This outcome will be compared between responders and non- responders of cardiac resynchronisation therapy</outcome>
      <timepoint>6 months post implantation of the biventricular pacemaker with or without a defibrillator</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients in whom CRT with or without Implantable Cardioverter Defibrillator (ICD) insertion is planned will be eligible for the study irrespective of the bases underlying heart failure</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>a.	Inability to attend for follow-up evaluation
b.	Treatment with inhibition of platelet ADP receptor activation e.g Clopidogrel
c.	Anticipated limitation of exercise capacity due to non cardiac disease eg Severe COPD
d.	Severe renal failure, Creatinine &gt;3mg/dl (265.2micromol/L) or on dialysis.
e.	Expected life expantancy less than 1 year due to non cardiac causes
f.	Inability to give informed consent
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>3/06/2013</anticipatedstartdate>
    <actualstartdate>6/08/2013</actualstartdate>
    <anticipatedenddate>4/09/2015</anticipatedenddate>
    <actualenddate />
    <samplesize>33</samplesize>
    <actualsamplesize>33</actualsamplesize>
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>The Queen Elizabeth Hospital - Woodville</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Lyell McEwin Hospital - Elizabeth Vale</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Queen Elizabeth Hospital Research Foundation</primarysponsorname>
    <primarysponsoraddress>28 Woodville Rd
Woodville South 
South Australia 5011</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>The Queen Elizabeth Hospital Research Foundation</fundingname>
      <fundingaddress>28 Woodville Rd
Woodville South
SA 5011</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The planned  studies will evaluate the central-peripheral interactions in cardiac resynchronisation therapy to determine the changes induced by the process and their various roles in modulating overall clinical response in patients with heart failure
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Human Research Ethics Committee (TQEH/LMH/MH) (EC00190)</ethicname>
      <ethicaddress>35a Woodville Road 
Woodville South
South Australia 5011</ethicaddress>
      <ethicapprovaldate>13/06/2013</ethicapprovaldate>
      <hrec>HREC/13/TQEHLMH/25</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>John Horowitz</name>
      <address>University of Adelaide/ The Queen Elizabeth Hospital
28 Woodville Rd
Woodville South
South Australia 5011</address>
      <phone>+61 8 8222 6000</phone>
      <fax />
      <email>John.Horowitz@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>John Horowitz</name>
      <address>University of Adelaide/ The Queen Elizabeth Hospital
28 Woodville Rd
Woodville South
South Australia 5011</address>
      <phone>+61 8 8222 6000</phone>
      <fax />
      <email>John.Horowitz@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Chukwudiebube Ajaero</name>
      <address>University of Adelaide/ The Queen Elizabeth Hospital
28 Woodville Rd
Woodville South
South Australia 5011</address>
      <phone>+61 8 8222 6000</phone>
      <fax />
      <email>Chuks.Ajaero@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>CHukwudiebube Ajaero</name>
      <address>University of Adelaide/ The Queen Elizabeth Hospital
28 Woodville Rd
Woodville South
South Australia 5011</address>
      <phone />
      <fax />
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>